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INTRODUCTION 
 
In the triad of anaesthesia, reflex suppression and facilitation of 
tracheal intubation is achieved by administering  neuromuscular blocking 
agents. An ideal muscle relaxant should have rapid onset, profound 
muscle relaxation  and short duration of action, so that patient’s own 
respiratory function can be  restored, should intubation proved to be 
impossible.1 Succinylcholine is the only available muscle relaxant for 
rapid tracheal  intubation.2 Its use is  associated with multiple 
complications like bradycardia, hyperkalemia, asystole, raised intraocular 
pressure, malignant hyperthermia,etc.3,4 Therefore need exists for a  
nondepolarizing muscle  relaxant with a rapid  onset of action. 
Rocuronium bromide is a new steroidal nondepolarizing 
neuromuscular  blocking agent shown to have rapid onset of action.5 
It has the fastest onset as compared to all other available nondepolarizing 
neuromuscular blockers, having an onset time similar to succinylcholine.6  
The onset time,duration and intubating conditions are influenced by the 
dose of rocuronium.    
 
  
AIM 
 
       This study is aimed at comparing  intubating  conditions in  
80 seconds by using three different doses of rocuronium bromide in 
adults by assessing the following parameters: 
1. The onset time and duration of neuromuscular blockade 
2.  Intubating conditions and 
3. Haemodynamic changes 
  
 
 
 
 
 
 
 
  
PHARMACOLOGY OF ROCURONIUM BROMIDE 
 
Org 9426 was synthesized and studies were undertaken in Organon 
Teknika Laboratories. It was later renamed as “Rocuronium Bromide” and 
introduced into clinical practice in 1994. 
CHEMISTRY: 
Rocuronium is the 2- morpholino, 3- desacetyl, 16- N-allyl –pyrolidino 
derivative of vecuronium bromide. It is a steroidal muscle relaxant of  
intermediate duration of action. The decreased potency of rocuronium 
bromide is due to the replacement of the methyl group attached to the 
quaternary nitrogen of vecuronium and pancuronium by an allyl group 
and the absence of acetylcholine –like fragment in the A ring. The 
replacement of an acetate group attached to the A ring by hydroxy group 
makes it stable in solution. 
MOLECULAR STRUCTURE 
 
  
 
 PRESENTATION : 
 It is supplied as a ready-to-use solution, in ampoules or vials of 
25mg(2.5 ml), 50mg(5 ml) and 100mg(10 ml).  It should be stored at 20C 
to 80 C in the dark. It can be stored at 80C to 300 C for 12 weeks. 
ROUTES OF ADMINISTRATION AND DOSAGE: 
Intravenous or intramuscular routes. 
ED95 dose is 0.3mg/kg . The standard dose required for intubation 
at 60seconds is  0.6mg/kg. It has a lag time of 25.8 seconds and onset 
time of 88.9 seconds. Intubating conditions can be improved by using 
high doses of 0.9mg/kg or 1.2mg/kg. 
The clinical duration of action for the 1×ED95 ,2×ED95 and  3×ED95 
doses are 15 minutes, 37 minutes and 53 minutes respectively. It is short 
acting with a dose of 0.3mg/kg(1×ED95) and intermediate duration of 
action with 0.6-0.9mg/kg. When more than 1mg/kg is used for intubation, 
onset is very quick (less than 45 seconds) but the duration of action is 
prolonged (more than 1 hour)  
For continuous infusion the dose is 5-10µg/kg/min (0.3-0.6 
mg/kg/hour).7 The infusion rate is adjusted to maintain twitch response at 
10% of control twitch height. 
 
 PHARMACOKINETICS: 
Rocuroniun is 30% bound to plasma proteins.  It has a smaller volume of 
distribution which reflects its lower lipophilicity when compared to 
vecuronium. 
TABLE-I 
Pharmacokinetics of Rocuronium bromide 
 
Age  Group 
Volume of 
distribution at 
steady state 
(ml/kg) 
Clearance       
(ml/kg/min) 
Elimination half 
life (min) 
Adult 207 2.89+/-0.25 70.9 +/-4.7 
Elderly 399+/-122 3.67+/-1 97+/-69.1 
Children 224 2.67 46-55 
 
Metabolism : 
The effect of rocuronium is terminated primarily due to liver 
uptake by a carrier mediated active transport system and excretion 
through the bile (>70%) either degraded or undegraded.8 The major 
putative metabolites 17-desacetyl rocuronium and 16N Desallyl 
rocuronium are pharmacologically inactive.   
 Liver disease increases the volume of distribution of rocuronium 
and could result in a longer duration of action  especially with repeated 
doses or prolonged IV administration. A small fraction of the 
administered dose (<20% )  is excreted by the kidneys. 
PHARMACODYNAMICS. 
Cardiovascular effects:  
Rocuronium has only minimal cardiovascular effects as evidenced 
by no changes in heart rate and arterial blood pressure with doses of 2-
3×ED95.19,20 The heart rate tends to increase with doses greater than 
5×ED95. The autonomic safety ratio for vagal block is about 10 times less 
than that of vecuronium. 
Histamine releasing property 
Rocuronium, being an aminosteroid is not associated with any 
increase in plasma histamine levels after rapid intravenous bolus injection 
of doses upto 4× ED95.21  
Anaphylactic or anaphylactoid reactions 
It is devoid of any significant histamine release. In terms of allergy, 
rocuronium appears to be very close to those aminosteroids relaxants with 
a good safety profile. 
 
 Cholinesterase inhibition 
 Inhibition of cholinesterase by certain muscle relaxants may lead 
to prolongation of effect of drugs dependant on cholinesterases for their 
metabolism, like suxamethonium and mivacurium. Atracurium and 
vecuroniun have very little activity on choliesterase activity. The 
anticholinesterase activity of rocuronium is lower than that of 
vecuronium. 
Central nervous  system 
Rocuronium has no effects on central nervous system since it does 
not cross the blood- brain barrier. There is no change in intracranial 
pressure.46 
Intra ocular pressure : 
 Rocuronium  has no significant effect on intra- ocular pressure. 
Rocuronium appears to be safe for use in rapid- sequence induction of 
anaesthesia for perforating eye injuries.47 
Placental transfer : 
Rocuronium does not cross the placenta in significant amounts.48 
 DRUG INTERACTIONS : 
Intravenous anaesthetic agents in standard doses like thiopentone, 
propofol,  etomidate,  midazolam,  fentanyl and droperidol do not have 
any clinically significant effect on the action of rocuronium. However, 
high doses of these drugs have a potentiating effect. 
Enflurane and isoflurane potentiate the effect of rocuronium.49 
Halothane appears to produce less potentiation of the block. Nitrous oxide 
does not have an effect on the depth of the block, although it causes some 
prolongation in recovery. The action of  rocuronium can be increased  in 
the presence of hypokalemia (eg;-patients on diuretics),  
hypermagnesemia (eclamptic patients on Magnesium sulphate therapy), 
hypocalcemia, hypoproteinemia, dehydration, acidosis, hypercapnia , 
hypothermia and cachexia.18 
Chronic administration of anticonvulsant drug phenytoin decreases 
the duration of action and increases the dose requirement of rocuronium. 
Single doses of commonly used antibiotics, metronidazole, cefuroxime, 
netilmycin and aminoglycosides do not have a significant effect on the 
action of rocuronium. 
 ROCURONIUM BROMIDE IN SPECIAL PATIENT GROUPS 
Paediatrics :  
In children, the onset of action is faster and the duration of action of 
rocuronium tend to be shorter. The action may be prolonged in neonates 
and infants due to increased volume of distribution and immature organ 
function.22  United States and Germany have strongly recommended  the 
use of rocuronium instead of succinylcholine in paediatric patients.23 
Rocuronium may be used for rapid sequence induction, as 
succinylcholine is relatively contraindicated because of the possible 
presence of undiagnosed muscle dystrophy especially in boys.24,25 
Recommended doses:  2 -12 years: 0.9 to 1.2mg/kg 
                                       Infants :  0.6 mg/kg              
                                      Neonates:0.45 mg/kg  
Geriatrics : 
The duration of action is prolonged in geriatric patients due to reduced 
volume of distribution, reduced organ based elimination and reduced 
plasma clearance.26 Both the onset and recovery are slower in the elderly.  
 Obstetrics : 
It does not cross placental barrier in significant amounts. 
Insignificant amounts of rocuronium are found in the milk of lactating 
rats. It can safely be used during rapid sequence induction of anaesthesia 
in patients undergoing caeserean section,  provided sufficient anaesthetic 
agent is used.48 Adequate intubation conditions are obtained within 80 
seconds following a 0.6 mg/kg dose; clinical duration of action is 33min.  
Placental transfer is limited, the average umbilical venous/maternal 
venous (UV/MV) ratio is 0.18. There are no untoward effects on the 
neonates evaluated by Apgar score(1minute & 5minutes), time to 
sustained respiration, total and muscular neuroadaptive capacity scores, 
acid–base status and blood -gas tensions in umbilical arterial and venous 
blood. 
Obese patients  : 
Obese patients  have metabolic alterations that may affect drug 
kinetics and dynamics. The onset of action is more rapid and the duration 
of relaxation is longer when the dose is based on actual body weight. If it 
is administered based on lean body mass, similar pharmacodynamic 
parameters are seen as in normal patients. 
Hepatic dysfunction : 
Plasma clearance of rocuronium is primarily due to liver uptake 
and biliary excretion. While its onset time is not altered, its duration of 
 action is significantly prolonged, but this is compensated to some extent 
by the larger volume of distribution.27  It should be avoided or used in 
decreased doses in patients with hepatic and/or biliary disease. 
Renal dysfunction : 
The clearance of rocuronium was reduced in patients with renal 
failure when compared with healthy patients  but its duration of action is 
not significantly altered. In severe renal impairment, it may be used in 
reduced doses. It is recommended that a reduced maintenance dose of 75 
to 100 micrograms/kg is used in patients with renal failure.  
Cardiac surgery : 
Its apparent lack of clinically significant cardiovascular effects 
makes rocuronium a suitable choice for cardiac surgery. But it lacks the 
cardiac stability of vecuronium in higher doses. 
Hypothermia : 
Hypothermia reduces plasma clearance of  rocuronium and 
prolongs its duration of action significantly, producing slower recovery. 
GENDER :                                                                                                      
The potency of rocuronium has been reported to be slightly greater 
in women than in men; the ED95  being 0.27mg/kg and 0.39mg/kg  
respectively, with an increased duration of action in women.28 
  
 
 PHYSIOLOGY OF NEUROMUSCULAR JUNCTION 
 
Neuromuscular Junction 
Neuromuscular junction is the synapse at which an electrical 
impulse travelling down a nerve is converted into muscle action potential 
and contraction by chemical transmitters. A motor neuron, along with all 
the muscle fibres supplied by it forms a motor unit, which follows all or 
none law of contraction. 
Mechanism of neuromuscular transmission 
Acetyl choline release: 
      An action potential travelling down the nerve causes the sodium 
channels in the presynaptic nerve terminal to open, leading to sodium 
influx. The change in voltage produced by such an impulse activates the 
calcium channels, which open up leading to calcium entry. Calcium 
mediated activation of  calcium calmodulin dependant protein kinases 
lead to phosphorylation of synapsins in the vesical wall causing the 
vesical walls to break away from the cytoskeletal framework. The 
vesicles then attach to the active zones with release of  Ach molecules. 
Each nerve impulse causes the release of around 100-400 quanta of Ach. 
Activation of around 20-25% receptors is essential for impulse 
transmission. 
  
 
 Acetyl choline binding to receptor : 
The Ach molecule released into the synaptic cleft binds to the 
alpha subunit. Binding of Ach to both the α subunits activates the 
receptor, leading to configurational changes in the receptor structure and 
opening up of ion channels. This leads to depolarization of the muscle 
end plate which when of a sufficient magnitude causes a wave of 
depolarization to spread across the muscle sarcolemma by means of 
activation of the voltage dependent gates of the sodium channels in the 
perijunctional zones. This depolarization wave moving down the T tubule 
causes release of calcium from sarcoplasmic reticulum. The released 
calcium binds to troponin C causing tropomyosin to move and expose the 
myosin binding sites of actin leading to the formation of cross linkage of 
actin and myosin heads.  They slide over each other leading to shortening 
of the myofilaments and muscle contraction. 
Dissociation of  acetylcholine from the receptor : 
The Ach molecule remains attached to its receptor for a very short 
period of less than one millisecond, after which it dissociates from the 
receptor and is hydrolysed by the enzyme acetylcholine esterase. It 
hydrolyses Ach into acetate and choline, the choline being taken up by 
the presynaptic nerve terminal and used for further Ach synthesis. 
 
 Non depolarizing (competitive) neuromuscular block: 
Non depolarizing muscle relaxants do not alter the structural 
conformation of the actylcholine receptor , but prevent depolarization by 
combining reversibly with one or both of the α-subunits, preventing 
access by acetylcholine and opening of the ion channel. This results in a 
lower endplate potential, which does not reach the threshold necessary to 
initiate an action potential. This is a dynamic situation with the various 
molecules repeatedly combining and being  released from the receptor. 
The neuromuscular transmission or block depends on the relative 
concentrations of acetyl choline and the blocking drug and their relative 
affinities for the postsynaptic nicotinic receptor. About 70-80% of 
receptors have to be occupied by a nondepolarizing drug before the 
response to nerve stimulation is affected.9 Thus during recovery from a 
non-depolarizing block, patients with a tidal volume of atleast 5ml/kg 
have 80% of acetyl choline receptors may still be occupied by the drug 
and 50% receptors are occupied when sustained head lift for 5seconds is 
elicitable. 
The phenomenon of fade and post-tetanic facilitation are thought to 
be due to block of the prejunctional nicotinic receptor. The blocking drug  
inhibits the positive acetylcholine feedback, which stimulates 
acetylcholine synthesis and mobilisation in the presynaptic nerve endings. 
 
 Features  of Nondepolarizing blockade: 
1. No muscle fasciculation. 
2. Slow onset to maximal effect and slow recovery compared to 
succinylcholine 
3. The central muscles like diaphragm, larynx, masseter, orbicularis 
oculi tend to be affected earlier and recover from the block sooner 
than those of the peripheral muscles like adductor pollicis probably 
due to preferential perfusion.10,11 
4. Presence of fade and post tetanic potentiation. 
5. Despite flaccid paralysis, the muscles are still able to respond to 
direct stimulation. 
6. The muscle block is reversed pharmacologically by 
anticholinesterases. 
7. Low potency drugs like rocuronium and rapacurium have rapid 
onset of action while potent relaxants like doxacurium and 
pancuronium have relatively slower onset of action and a longer 
duration of action.12,13   
Rocuronium produces muscle paralysis by competitive antagonism 
of nicotinic cholinergic receptors of skeletal muscles. Its potency is about 
15-20 percent of that of vecuronium. With equipotent doses, onset of 
 rocuronium at the adductor pollicis muscle is much faster than that of 
atracurium and vecuronium.14  It has an intermediate duration of action, a 
rapid recovery and shows minimal cumulation. Paralysis occurs first in 
the well perfused fast muscles and last in the diaphragm.15 Onset of block 
is faster, but less intense at the diaphragm and adductor muscles of the 
larynx than  at adductor pollicis muscle.17 The diaphragm  is affected later 
but recovers earlier than the adductor pollicis. Nondepolarizing block 
produced by rocuronium is antagonised by anticholinesterases. 
NEURO  MUSCULAR  MONITORING 
Muscle relaxants have come in routine use and have become vital 
to the care and well being of patients undergoing anaesthesia and surgery. 
In most instances adequacy of neuromuscular relaxation and recovery 
from neuromuscular  blockade is judged clinically. Sudden recovery from 
muscle relaxant effect in the middle of the surgical procedure and 
postanaesthetic recurarisation are still common.Therefore,  monitoring 
the neuromuscular blockade using neuromuscular monitor is essential. 
Neuromucular blocking drugs have a narrow therapeutic index and there 
is wide interindividual variability.So, it is wise to monitor their effect in 
all patients. The response of muscle to nerve stimulation should be 
assessed to know about the status of neuromuscular functioning precisely.  
By monitoring the neuromuscular blockade, sufficiency of relaxation to 
tracheal intubation  can be determined, adequacy of surgical relaxation 
 can be maintained and immediate postoperative critical events like 
ventilatory insufficiency  and hypoxemia and delayed complication like 
pulmonary infection could be prevented. 
CLINICAL APPLICATION                                                                                 
The narrow margin of safety and the intention to provide a 
balanced  adequate surgical relaxation with safe restoration of function at 
the end of procedure makes neuromuscular monitoring an important tool. 
Intubation: 
Onset of block and adequacy of intubating conditions can be 
assessed using TOF stimulation. Orbicularis oculi can be used for 
procedures where perfect immobilisation is required during intubation as 
in case of increased ICP or open eye injury. 
Maintenance of block : 
         Adequate relaxation for abdominal surgery is generally correlated 
with 1-2 twitches of  TOF. Diaphragm is relatively resistant and requires 
more neuromuscular blockade. Intraoperatively, the intensity of blockade 
may be assessed if necessary using post tetanic count. 
Detecting recovery from neuromuscular blockade : 
 When the TOF ratio is 0.4 or less, the patient is generally unable 
to lift the head or arm. Tidal volume may be normal, but the vital capacity 
and inspiratory force will be reduced. 
 When the ratio is 0.6, most patients are able to lift the head for 3 seconds, 
open the eyes widely and stick out the tongue. 
At a TOF ratio of 0.7 to 0.75, the patient can normally cogh sufficiently, 
and lift the head for atleast 5 seconds, but the grip strength may still be 
low. 
When the ratio is 0.8 and higher, vital capacity and inspiratory force are 
normal. The patient may, however, still have diplopia and facial 
weakness. 
TOF ratio must exceed 0.8 or even 0.9 to exclude clinically important 
residual   neuromuscular blockade  .  
Residual block (TOF ratio < 0.9 ) is associated with functional 
impairment of muscles of pharynx and upper esophagus, predisposing to 
regurgitation and aspiration. 
In long term rehabilitation in ICU: 
Residual paralysis due to NMB can lead to polyneuropathy and  
myopathy requiring ventilatory support for a long duration after 
termination of muscle relaxant. Minimal use of NMB can prevent long 
term residual paralysis. Patient can be maintained at T1 or T2 of TOF 
stimuli for quick recovery.   
 
  
NERVE STIMULATOR  NS‐100 
  PRINCIPLE OF NERVE STIMULATION 
The current strength is the determining factor in nerve stimulation. 
Threshold current  is the amount of current required  to elicit a detectable  
response . It is about 15mA, when surface electrode is applied. Maximal 
current is the amount of  current needed to induce depolarization in all the 
nerve fibers of the nerve bundle and evoke maximal response from the 
muscle. 
Supramaximal  current is 10—20% more than maximal current or 
2.75 times more than threshold current. The resistance  can be reduced by 
removing the hair, decornifying and de-creasing the skin. 
Neuromuscular function is monitored by evaluating the muscular 
response  to supramaximal electrical stimulation of a peripheral motor 
nerve. The response of the whole muscle depends on the number of nerve 
fibers activated. If a nerve is stimulated with sufficient intensity, all the 
muscle fibres supplied by that nerve will react and the maximum 
response will be triggered. After administration of a neuromuscular 
blocking drug, the response of the muscle decreases in parallel with 
number of fibres blocked. The reduction in response during constant 
stimulation reflects the degree of neuromuscular blockade.  
The stimulating wave form should be rectangular (square wave)  
and monophasic, so that current is maintained throughout the stimulus.  
 The frequencies  of stimulus is expressed in Hertz(hz). 1 Hz= 1 
cycle/sec.The usual frequency for various types of stimulations ranges 
from 0.1 Hz—100Hz 
Surface gel coated electrodes for electrocardiogram can be used. 
With large electrodes conducting area is large, obtaining a supramaximal 
stimulus will be difficult. Small paediatric electrodes can be used to avoid 
stimulation of neighbouring nerves. Needle electrodes may be used in 
thick skinned and obese patients.  
Sites of nerve stimulation 
Electrode Nerve Muscle Response 
Ulnar aspect of 
wrist 
Ulnar Nerve Adductor 
pollicis 
Adduction of 
thumb 
Behind 
ascending 
ramus 
Facial N Superficial 
facial muscles 
Movements of 
muscles of 
facial 
expression 
Beneath 
zygomatic arch 
Mandibular N Masseter Jaw contraction 
Laterally above 
zygomatic arch 
Facial N Orbicularis 
oculi 
Eye blink 
Head of fibula Superficial 
peroneal.N 
Tibialis anterior Dorsiflexion of 
foot 
Behind lateral 
malleolus 
Post. Tibial N. Extensor 
hallucis 
Dorsiflexion of 
great toe 
 TRAIN OF FOUR STIMULUS 
In TOF,  four supramaximal stimuli are given every 0.5 seconds, 
that is at a frequency of  2 Hz. Each set (train) of stimuli is repeated every 
tenth to twelfth second, when used continuously. 
Each stimulus in the train  cause the muscle to contract if neuromuscular 
transmission is normal. With neuromuscular blockade,  there is a decrease 
in amplitude of response. 
a. With a partial non-depolarizing block, there is a fade in the 
response, that is the amplitude of the response decreases gradually 
from the first to the fourth response. 
Dividing the amplitude of the fourth response by the amplitude of 
the first response provides the TOF  ratio. The ratio is inversely 
proportional to the degree of NMB. 
b. With a depolarizing block , there is a decrease in amplitude of all 
the four responses compared to the control. No fade occurs in the 
TOF response. 
USES: 
1. To judge the onset of blockade : Tracheal intubation may be 
attempted when the response to single twitch or TOF is noted to  
weaken visibly. 
 2. To  judge the depth of block : Intraoperatively, depth of 
neuromuscular blockade  is assessed by monitoring the response to 
TOF   
Intense blockade—no response to TOF 
Moderate or surgical blockade- 1or 2 response to TOF is present  
Number of responses detected Degree of neuromuscular blockade 
1 95% 
2 90% 
3 80% 
4 75% 
 
3. To judge the adequacy of recovery from block : When the third or 
fourth response to TOF stimulation appears, adequate recovery can be 
achieved within 5 minutes of neostigmine administration. 
4. TOF monitoring is far less painful than tetanic stimulation. It can be 
performed in awake sedated patient. 
Other Patterns of stimulation 
1. Single twitch stimuli  
In this, supramaximal stimuli are applied to a peripheral motor 
nerve at frequencies ranging from 0.1Hz to 1 Hz.  A control twitch height 
should be measured before administering  muscle relaxant. Twitch height 
 remains normal until 75% of receptors are blocked and disappears when 
90% of acetylcholine receptors are blocked. This method can be used to 
ascertain  adequacy of  muscle relaxation for tracheal intubation.  
 
2. Tetanic Stimulation 
Used to evaluate residual neuromuscular blockade. During normal 
neuromuscular transmission and a pure depolarizing block, the muscle 
response to 50-Hz tetanic stimulation for 5 seconds is sustained. During a 
partial  nondepolarizing block, the response will not be sustained ie.,fade 
occurs. Post  tetanic  potentiation is the enhancement of response to 
single twitch stimuli , which is applied two minutes after the appearance 
of fade to  tetanic stimulation.  Tetanic stimulation is painful and should 
not be applied on conscious patient.  
   
3. Post tetanic count 
The principle of post tetanic facilitation is used where 50 Hz 
tetanic stimulation is applied for 5 seconds, then after an interval of 3 
seconds, a supramaximal stimuli is delivered every second. The number 
of evoked post tetanic twitch detected is called post tetanic count (PTC).  
The main application of PTC is to evaluate the degree of neuromuscular 
blockade when there is no response to single twitch or TOF after 
administering large dose of non-depolarizing block.  PTC is useful to 
maintain profound muscle relaxation whenever sudden  patient movement 
 must be avoided as in ophthalmic surgery and intubation in raised ICP 
where the PTC count should be “O” (Zero). PTC helps to estimate the 
time interval to recover from intense muscle blockade. The PTC 
correlates inversely with the time required for a return of single twitch or 
TOF responses.For intermediate-duration drugs, the time from a PTC of 1 
to reappearance of twitch is 15 to 20 minutes.  
 
PTC- 0/1  - Intense block  
3  - Less intense block 
8-10   - Surgical block  
 
 
4. Double burst stimulation:  
Double burst stimulation (DBS) was developed to allow the 
clinician to detect subtle degree of NMB without the use of recording 
devices.   Two short burst of  tetanic stimuli delivered at a frequency of 
50 Hz are repeated by a 750 ms interval.  Each burst consists of series of 
3 and 2 impulse (DBS3,2) or 3 and 3 impulses (DBS3,3).  A good 
correlation between  DBS3,3 ratio and TOF ratio had been demonstrated. 
During recovery and immediately after surgery, tactile evaluation of the 
response to DBS3,3 is superior to tactile evaluation of the response to TOF 
stimulation.     
 
 Methods for Recording of  Evoked  Responses :- 
1). Visual and Tactile measurement 
The simplest way of recording the response  is to look and feel for 
it 
2). Mechanomyography 
3). Electromyography 
4). Acceleromyography 
 
characteristic Depolarizing NMB 
(partial) 
Nondepolarzing 
NMB (partial) 
Tetanic stimulation No fade Fade 
Post-tetanic facilitation None Yes 
Train –of-four No fade Marked fade 
 REVIEW OF LITERATURE 
 
Rocuronium, a non-depolarizing neuromuscular blocker was 
brought into clinical practice in the mid ninties. 
Dose of Rocuronium may influence the onset and duration of 
action. Literature was reviewed to compare the intubating conditions  
with varying doses of rocuronium. 
1.Jamshid  Ali, Showkat Ahmad Gurckoo , Asaf Shora and 
Shagufta Qazi in 2008, studied intubating conditions of rocuronium 
bromide and succinylcholine during rapid sequence induction of 
anaesthesia in adult patients. The main variables assessed in these 
patients were intubating conditions at 60 or 90 seconds after 
administration of neuromuscular blocking agent according to four point 
scale of Cooper  et al. They concluded that it was safe to use rocuronium 
for rapid sequence induction, but intubating conditions after 0.6mg/kg  
rocuronium at 60secs of assessment were not satisfactory in a significant 
number of cases. Therefore,they suggested that higher doses of 
rocuronium (0.9—1.2mg/kg) should be used for rapid sequence induction 
of anaesthesia especially if the anticipated surgical time is prolonged. 
2.Claudia A.Y. Cheng Fanzca and Cindy S.T.Aun MD.,21,May 
2001, compared rocuronium(0.6mg/kg&0.9mg/kg) and suxamethonium 
for rapid tracheal intubation in children. Differences between 
 suxamethonium and rocuronium 0.6 mg/kg and between the two doses of 
rocuronium were statistically significant (P=0.016 and 0.007, 
respectively).They concluded rocuronium 0.9 mg/kg provides similar 
intubating conditions to suxamethonium  1.5 mg/kg  during “modified  
rapid sequence induction” using alfentanil and thiopentone in children 
(P=0.671). Rocuronium 0.6 mg/kg was inadequate. 
3. K.C.Mc. Court, L.Salmela, R.K.Mirakhur and M.Carroll 
,1998;53(9):867-71 compared rocuronium and suxamethonium for use 
during rapid sequence induction of anaesthesia  
This study was designed to compare the tracheal intubating 
conditions during rapid sequence induction of anaesthesia using 
rocuronium 0.6 (n = 61) or 1.0 mg.kg-1 (n = 130) or suxamethonium 1.0 
mg.kg-1 (n=127) as the neuromuscular blocking drugs. Anaesthesia was 
induced with fentanyl 1-2μg.kg-1 and thiopentone 5 mg.kg-1 (median 
dose) and intubating conditions were assessed 60 seconds after the 
administration of the neuromuscular blocking drug by an observer, who 
was not aware of the drug  given. Intubating conditions were graded on a 
three-point scale as excellent, good or poor, the first two being 
considered as clinically acceptable. The study was carried out in two 
parts. At the end of the first part a comparison between the two doses of 
rocuronium was carried out when at least 50 patients had been enrolled in 
each group. The results showed the intubating conditions to be 
 significantly superior with the 1.0 mg.kg-1 dose of rocuronium (p<0.01). 
Final comparison between the 1.0 mg.kg-1 doses of rocuronium and 
suxamethonium showed no significant difference in the incidence of 
acceptable intubations (96 and 97%, respectively). The incidence of 
excellent grade of intubations was, however, significantly higher with 
suxamethonium (80% vs. 65%; p=0.02). It was concluded that 
rocuronium 1.0 mg.kg-1 could be used as an alternative to suxamethonium 
1.0 mg.kg-1 as part of a rapid sequence induction provided there is no 
anticipated difficulty in intubation. The clinical duration of this dose of 
rocuronium was, however, 50-60 minutes. 
4. Anestesiol. vol.54 no.2 Campinas Mar./Apr. 2004 Maria 
Cristina Simões de Almeida, TSA, M.D.I; Rogério Silveira Martins, TSA, 
M.D.II; Ana Lúcia Costa Martins, M.D.I  
 This study aimed at comparing intubation conditions after 0.6 
mg.kg-1 rocuronium at 60 seconds in children, adults and elderly patients. 
METHODS:  60 ASA I,II,III patients aged 1 to 88 years who were 
divided in three groups according to age: Group 1 (G1) children up to 12 
years of age; Group 2 (G2), adults aged 18 to 65 years; Group 3 (G3) 
patients above 65 years of age. 
CONCLUSIONS: In the conditions of their study, 0.6 mg.kg-1 
rocuronium was sufficient for tracheal intubation in 60 seconds in adult 
 and elderly patients. It was, however, insufficient for clinically acceptable  
intubating conditions in 60 seconds in 100% of children. 
Patients were premedicated with 7.5 to 15 mg midazolam oral 
(adults and elderly), or 0.5 to 1 mg.kg-1 for children (maximum 15 mg 
orally).  After preoxygenation with 100% O2 for 3 minutes, anesthesia 
was induced with  fentanyl(3 to 5 µg.kg-1) and propofol 3 to 4 mg.kg-1 
(children) or 2 to 3 mg.kg-1  (adults and elderly) . All patients received 
rocuronium in the fixed dose of 0.6 mg.kg–1 in 5 seconds and tracheal 
intubation was performed  60 seconds after rocuronium injection. For 0.6 
mg.kg-1 rocuronium, optimal time to obtain best intubating condition is 
approximately 70 seconds. Other authors, however, have emphasized that 
tracheal intubating conditions with 0.6 mg.kg-1  rocuronium are poorer 
than those obtained with 1mg.kg-1 succinylcholine . So,the current trend 
is to administer 0.9 to 1.2 mg.kg-1 rocuronium when the aim is to replace 
succinylcholine. 
 For fast and safe induction, it is important that, in addition to 
laryngeal muscles,diaphragm and intercostal muscles are also blocked to 
prevent tracheal tube or cuff reactions like bucking or coughing after its 
placement.   
5.Ali A. Sheikh N A, Khawaja S, Saleem J and Kaul S U., in March 
2008, studied to find out whether rocuronium produces intubating 
conditions as good as suxamethonium in Rapid Sequence Induction  
 (RSI) in elective caesarean section. In their study, they found that 
clinically acceptable  intubating conditions (good and excellent) were 
similar with both groups, although the rate of excellent intubating 
conditions was higher with suxamethonium that was not statistically 
significant. Their study showed that rocuronium 1.0 mg/kg provides 
equally good intubating conditions when compared with suxamethonium 
1.5 mg/kg in elective caesarean section in 60 seconds using RSI. 
6.Mazurek A J ; Hann  S. compared rocuronium versus 
succinylcholine for rapid sequence induction and concluded that larger 
doses of rocuronium may be an alternative to suxamethonium.  
7.MC Donald PF, Sanisbary DA, evaluated onset time and 
intubating conditions of rocuronium bromide in children  and concluded 
that intubating conditions are achieved faster with rocuronium compared 
to other non depolarizing relaxants.  
 
8.DE Mey J.C DE Brock M, et al., in 1994 evaluated the onset and 
intubating conditions of rocuronium bromide in three doses of 0.6 mg/kg, 
0.75 mg/kg and 0.9 mg/kg. They found acceptable intubating conditions 
with 0.6 mg/kg dose at 60 seconds. The onset time ranged from 1 to 1.7 
minutes. Increasing the dose, improved intubating conditions and reduced 
onset time.The duration of action with 0.6 mg/kg was 27.3 ± 8.2 minutes, 
 with 0.75 mg/kg was 43.6 ±12.0 minutes and 0.9 mg/kg was 53.0 ±15.2 
minutes. 
9.Stoddart compared intubating conditions of rocuronium 
0.6mg/kg with suxamethonium 1 mg/kg for tonsillectomy patients and 
onset time was 92 seconds and 42 seconds respectively.  
10.J. Viby – Mogenson observed that the average clinical duration 
of action of intubating dose is shorter in children than adults which may 
be due to large volume of distribution of control compartment in children.  
11.Watanabe K, Chen K., et al (1991)  described the pre and 
postsynaptic effects of org 9426 (Rocuronium) during the onset and 
recovery from neuromuscular blockade. They found the relaxant to have 
moderate potency with rapid onset time, intermediate duration of action 
and rapid recovery. 
 12.Crul JF, Vanbelleghem V, et al., in 1995 studied intubating 
conditions of rocuronium bromide with alfentanil and propofol at 45 
seconds,  with a dose of 0.6 mg/kg.They obtained excellent intubating  
conditions in 60% and good conditions in 60%.  In a dose of 0.9mg/kg, 
they obtained excellent intubating conditions in 89% and good conditions 
in 11%. 
13.Jean Paul Cantineau, et al (1994) found that the diapharam is 
more resistant than the adductor pollicis to rocuronium 0.6 mg/kg. The 
onset time for muscle relaxation after 0.6 mg/kg rocuronium was shorter 
for the adductor pollicis muscle than for the diaphragm (80+/- 20 Vs 120 
 +/-62sec).  Time for 10%, 25%, 75% and 90% recovery of twitch height 
were 34+/- 10, 40+/-10, 56+/-20 and 64+/-21 minutes, respectively for 
the adductor pollicis and significantly shorter for the diaphragm, 17+/-10, 
23+/-9, 33+/-13, 35+/-10 minutes respectively.   The intubating dose of 
0.6mg/kg is close to ED95 of 0.5mg/kg for the diaphragm.  
14. Peter M.C Wright., et al (1994) studied the onset and duration 
of rocuronium and succinylcholine at the adductor pollicis and laryngeal 
adductor muscles in anaesthetized adults.  They found that the onset of 
action with succinylcholine was significantly more rapid at the laryngeal 
adductors (34+/-12 sec) than at the adductor  pollicis (56+/-15 sec).  
Onset times were similar at the two muscle groups with rocuronium 0.8 
and 1.2mg  (96+/-29 and 74+/-36 sec.  with 0.8 mg/kg and 54+/-30 and 
65+/- sec with 1.2 mg/kg at the laryngeal adductors and the adductor 
pollicis, respectively.)      Rocuronium 0.4mg/kg had a more rapid effect 
at the laryngeal adductors than the adductor pollicis (92+/-29 sec. and 
155+/- sec. respectively.)   They concluded that the laryngeal adductors 
are more resistant to the action of rocuronium than is the adductor 
pollicis.  Onset of effect of rocuronium in doses greater than 0.8mg/kg is 
similar to that of succinycholine at the adductor pollicis but is 
significantly delayed compared with that of succinycholine at the 
laryngeal adductors. 
 
 15.Cooper R, Mirakhur RK, et al.,  in 1992 compared the 
intubating conditions after administration of rocuronium 0.6mg/kg and 
suxamethonium 1 mg/kg at 60 seconds. In the rocuronium group, the 
intubating conditions were   excellent in 14/20, good in 4/20 and fair to 
poor in 2/20 . In the suxamethonium group, the intubating conditions 
were   excellent in 19/20 and good in 1/20.They recorded an onset time of 
88.9 seconds and duration of 30.5 + 7.5 minutes for rocuronium in a dose 
of 0.6 mg/kg 
16.Muir AW, Anderson KA, et al., in 1994  studied the interactions 
between rocuronium bromide and some drugs used during anaesthesia.    
They concluded that halothane, isoflurane and enflurane  significantly 
reduced the dose requirement of rocuronium.   The duration of action was 
markedly potentiated by enflurane and only slightly by halothane.   
Nitrous oxide did not affect the dose or duration of rocuronium. Among  
I.V anaesthetics, thiopentone and ketamine moderately potentiated the 
action of rocuronium. Propofol and alfentanil had a minimal effect.   
Morphine and chlorpromazine produced some potentiation of action of 
rocuronium.  Streptomycin appears to potentiate its effect too. 
17.Kirkegaard – Nielsen H., et al., (1999)  studied rapid tracheal 
intubation with rocuronium using a probability based approach. 80 adult 
patients anaesthetized with fentanyl 2 µg/kg and propofol 2mg/kg 
randomly received rocuronium  0.4, 0.8, or 1.2 mg/kg (n=20/dose).  
Laryngoscopy was initiated at 40 seconds aiming for intubation at 60 
 seconds.   Doses giving 90% and 95% probability of successful intubation 
were calculated and found to be 0.83 and 1.04 mg/kg respectively.  
Estimated time to obtain first tactile train of four response after ED50 and 
ED95 doses were 32 and 46 minutes respectively. They concluded that 
after induction with fentanyl and propofol, rocurionium 1.04 mg/kg gives 
95% probability of successful intubation at 60 seconds.  
 
18.Levy JH, Davis G,  et al.,  in 1994 determined the 
haemodynamics and histamine release of rocuronium bromide over 2,3 
and 4 x ED95 doses.  They found no statistically  significant differences 
among the groups with respect to heart rate, systolic blood pressure, mean 
arterial pressure and histamine release at peak effect for the initial 6 
minutes after the bolus dose.   They concluded stability even when used 
in doses upto 4 x ED95 
19.Andrews JI., et al (1999) compared rocuronium and 
succinylcholine for rapid sequence induction of anaesthesia along with 
propofol and anesthesia was induced using propofol 2.5mg/kg followed 
immediately by either rocuronium 0.6mg/kg or 1 mg/kg or 
succinylcholine 1mg/kg .  Intubating conditions were assessed at one 
minute and intubation was performed.  They concluded that rocuronium 
1mg/kg given along with propofol in a rapid sequence induction of 
anaesthesia is clinically equivalent to succinylcholine 1mg/kg. 
 
 20.Magorian T, Flannery KB, et al., in 1993 evaluated the onset time and 
duration of action of rocuronium  in 3 dosage schedules.  A dose of 0.6 
mg/kg had a onset time of 89 seconds with a duration of action ranging 
from 23 to 75 minutes with a mean of 37 minutes. In a  0.9 mg/kg dose, 
the onset time was 75 seconds and duration of action ranging  from 25 to 
88 with a mean of 53 minutes. In a 1.2 mg/kg dose, onset time was 55 
seconds & a duration of action ranging from 38 to 150 with a mean of 73 
minutes. 
 
 MATERIALS AND METHODS 
 
This study was conducted in 60  patients who met the study criteria 
and underwent general anaesthesia with endotracheal intubation.  
DESIGN OF STUDY:-  
It is a Comparative  Prospective Randomized clinical trial study. 
The study was approved by the Ethical Committe and done during the 
period from May 2009 to August 2009 in the department of 
anaesthesiology, Chengalpattu medical college hospital, Chengalpattu. 
The surgeon was also duly informed of the study. 
The inclusion criteria were:- 
1. Patients of ASA grade I and II of either sex 
2. MPC I and II 
3. Age group of 25 to 45 years 
4. Elective surgeries posted under G.A. 
The exclusion criteria were :- 
1.Known or anticipated difficult airways 
2.Patients with neuromuscular disease 
3.Drugs known to interact with neuromuscular blocking agents 
 4.Family H/O Malignant Hyperthermia 
5.Renal or Hepatic disorder 
6.Known allergy to drugs 
Sixty patients who  fulfilled the eligibility criteria were enrolled for 
the study. Preoperatively informed, written consent was obtained from  
these patients. These patients were systematically randomized into three 
groups of twenty each. 
Group 1 ----- Thiopentone 5mg/kg +  Rocuronium 0.6 mg/kg 
Group 2----- Thiopentone 5mg/kg +  Rocuronium 0.9 mg/kg 
Group 3----- Thiopentone 5mg/kg +  Rocuronium 1.2 mg/kg 
 PREOPERATIVE EVALUATION 
  In all patients, age, I.P.No., baseline vital parameters were 
recorded. History regarding previous anaesthesia, surgery, any 
significant medical illness , medications and allergy were recorded. 
Complete physical examination and airway assessment was done. 
Following laboratory investigations were done:- 
Haemoglobin %  Urine-  Albumin and sugar, Packed cell volume   
Blood- urea, sugar, creatinine, Liver Function Tests, E.C.G.  X-Ray Chest 
  
 
 ANAESTHESIA PROTOCOL 
Pre operative visit was done to allay anxiety and good rapport was 
established with the patient and the procedure was explained to the 
patient. 
PREMEDICATION 
All patients received Inj. Pentazocine 0.5mg/kg  and Inj. 
Glycopyrollate  10µg/kg I.M. 45 minutes prior to surgery. 
INDUCTION OF ANAESTHESIA 
After  shifting the patient to operation theatre, intravenous line was 
secured using 18G cannula in a vein in the dorsum of hand and 
maintenance intravenous fluids were started. 
Following monitors were connected to the patients : 
1.Non invasive blood pressure    
2. Electro cardiogram monitor 
3. Pulse oximeter 
4. Neuromuscular monitor 
For stimulation of the ulnar nerve ,the electrodes are best applied at 
the volar side of the wrist   The  Ulnar nerve motor point is located  15—
 25mm proximal to the pisiform bone on the thumb side of the 
flexorcarpiulnaris tendon. 
The  distal electrode  was placed about 1cm proximal to the point 
at which the proximal flexion crease of the wrist crosses the radial side of 
the tendon to the flexor carpi ulnaris muscle. The proximal electrode was 
placed 2-5 cm proximal to the distal electrode29. With this placement of 
electrodes, electrical stimulation normally elicits only finger flexion and 
thumb adduction. Polarity of the electrodes is less crucial when both 
electrodes are close to each other at the volar side of the wrist; however, 
placement of the negative electrode distally normally elicits the greatest 
neuromuscular response. 
The patient was preoxygenated for 3 minutes and then induced 
with Inj.Thiopentone  5mg/kg 2.5% solution given over 15 seconds. 
Following loss of consciousness , the ulnar nerve was stimulated at the 
wrist using  peripheral nerve stimulator.The current strength was 
progressively increased and the single twitch elicited. When the maximal 
thumb adduction was obtained the current strength was noted and one and 
half times the strength was used for elicitation of Train Of Four 
Stimulus.The HR and B.P. with supramaximal stimulus were noted. 
A bolus i.v. dose of  Inj.Rocuronium 0.6mg/kg(2× ED95) or 
Inj.Rocuronium 0.9mg/kg(3× ED95) or Inj.Rocuronium 1.2mg/kg(4× 
ED95)  depending on the group was given over a period of in 5 seconds. 
 Patient was ventilated with 100% oxygen. TOF was elicited  every 10 
seconds and the trachea was intubated after 80 seconds with appropriate 
size endotracheal tube after doing a proper laryngoscopy. Endotracheal 
tube was secured after confirming bilateral air entry. The conditions of 
intubation were evaluated and scored  according to the scoring system 
described by Cooper et al. 
The time from the end of injection of the relaxant to the time when 
all four responses of TOF were abolished was taken as onset time.  
After intubation and observation of the intubating conditions and 
haemodynamic profiles, anaesthesia was maintained with 33.3% oxygen 
and 66.7% nitrous oxide using closed circuit system with controlled 
ventilation.  B.P. and Pulse  Rate were recored 1minute, 3minuutes  and 
5minutes  after  injection of the relaxant. Volatile anaesthetics were not 
used in this study. 
Neuromuscular function was monitored using TOF stimuli every 
5minutes. The  interval between the administration of the  bolus dose of 
the relaxant and the reappearance of the two responses to TOF was taken 
as the duration of action. 
 OBSERVATIONS AND RESULTS 
The following observations were recorded :- 
1. The mean onset of neuromuscular blockade and duration of action 
were calculated for all the three groups. 
2. The heart rate, systolic pressure, diastolic pressure, mean arterial 
pressure were recorded  before induction, during intubation and 1minute, 
3minutes and 5 minutes after intubation and compared between the three 
groups 
3. Intubating conditions  were scored by a scoring system used by 
Mirakhar R.K. , Cooper A.R. and  Clark R.S.J30.  (Table II  and Table 
III). The scores for jaw relaxation, vocal cord position and response to 
intubation and the total scores are compared between the 3 groups . 
TABLE II 
Scoring of Intubating Conditions 
Score Jaw relaxation Vocal Cords Response to intubation 
0 Poor (impossible) Closed Severe coughing or bucking 
1 Minimal(difficult) Closing Mild coughing 
2 Moderate (fair) Moving Slight diaphragmatic movement 
3 Good  (easy) Open None 
 TABLE III                       GRADING 
Intubating Conditions Score 
Excellent 8—9 
Good 6—7 
Fair 3—5 
Poor 0—2 
 
STATISTICAL EVALUATION 
All recorded data were entered using MS Excel software and 
analyzed using STATA software for determining the statistical 
significance.  Analysis of Variance (ANOVA) was used to study the 
significance of mean of various study parameters among the three groups. 
Student’s ‛t’ test was used to compare the two groups on mean values of 
various parameters. The p-value taken for significance is 0.05.  
 The study was conducted  on 60 patients randomly allocated into 3 
groups as given below :- 
DRUG AND DOSAGE SCHEDULE 
Group Number of cases Drug & Dosage 
1 20 Rocuronium 0.6mg/kg 
2 20 Rocuronium 0.9mg/kg 
3 20 Rocuronium 1.2mg/kg 
Statistical analysis : 
TABLE IV                Demographic profile 
 GROUP 1 GROUP 2 GROUP 3 P 
GENDER (M/F) 5/15 13/7 15/5  
AGE(YEARS) 
MEAN±SD 
25.5±6.6 31.9±7.1 29.2±6.7 <0.05 
WEIGHT (KG) 
MEAN±SD 
51.2±10.8 51.8±14.1 52.95±8 >0.05 
More female patients are present in Group-1 and more male patients in 
Group-3. More younger patients in Group-1.  The age difference among 
the groups observed  is statistically significant (p <0.05). But there is no 
significant difference between the three groups regarding weight of the 
patient. 
  
 
 
 
 
 TABLE V                       Jaw relaxation 
 IMPOSSIBLE  TO OPEN 
OPEN WITH 
DIFFICULTY 
MODERATE 
OPENING 
EASY 
OPENING 
MEAN 
±SD 
GROUP1 1 6 11 2 1.7± 0.7
GROUP2 0 0 6 14 2.7± 0.5
GROUP3 0 0 6 14 2.7± 0.5
 
 
 Mean Jaw Relaxation  
 
There is significant difference among the three groups on Mean Jaw 
Relaxation (p <0.05), but there is no significant difference between 
group-2 and group-3. 
TABLE VI                         Vocal Cord Position 
 
0-
CLOSED 
1-
CLOSING
2-MOVING 
MOVEMENT
3-OPEN 
RELAXED 
     
MEAN 
±SD        
GROUP 1 3 7 7 3 1.5± 0.9
GROUP 2 0 1 5 14 2.7 ±0.6
GROUP 3 0 1 4 15 2.7± 0.6
 
  
Vocal cord position 
 
There is significant difference among  the three groups on Mean 
vocal cord position (p <0.05), but there is no significant difference 
between group-2 and group-3. 
 
  Table VII                    Response to Intubation           
 SEVERE COUGHING 
MILD 
COUGHING
SLIGHT 
DIAPHRAGM 
MOVEMENT 
NO 
MOVEMENT 
MEAN 
±SD 
GROUP 
1 2 7 9 2 
1.6± 0.8 
GROUP 
2 0 0 5 15 
2.8 ±0.4 
GROUP 
3 0 0 4 16 
2.8± 0.4 
 
 
 
 
 
 
  
Response to Intubation 
 
There is significant difference among  the three groups on Mean 
Response to intubation  (p <0.05), but there is no significant 
difference between group-2 and group-3. 
 
GROUP I  VS  GROUPII   P=0.001      - Significant 
GROUP I  VS  GROUPIII  P=0.001      - Significant 
GROUP II  VS  GROUPIII  P=0.79      -Not  significant 
 MEAN ± STANDARD DEVIATION (MINIMUM-- MAXIMUM) 
TABLE VIII                           HR 
TIME GROUP 1 GROUP 2 GROUP 3 P 
VALUE 
BASELINE 90.3± 10.3 
(70–108) 
90.2± 11.3  
(76–120)   
90.15± 9.9  
(76–110) 
>0.05 
INDUCTION 94 ± 9.1  
(76–112) 
93±11.9       
(80– 126)   
94.3±9.7       
(80–112) 
>0.05 
INTUBATION 108± 11 
(90–126) 
96.4±12.9    
(82–128)   
99.15±10.3   
(84–120)   
<0.05 
1 MIN 110±11.7      
(94– 130) 
93.05±10.4 
(80–114)   
95.65±9.5     
(80–116)    
<0.05 
3 MIN 108.25±12.6 
(90–136)   
90.5±11.2    
(78–119)  
90.3±8.7       
(80–110)   
<0.05 
5 MIN 99.9±11.2     
(86–126) 
86.4± 10.3  
(74 –122) 
85.65± 6.4  
(74 –98) 
<0.05 
 
There is 5-40% increase in Heart Rate from baseline on monitoring 
the patients  in Group-1 ,5-20%  in Group-2 and Group-3. The higher HR 
observed at 1st minute in Group-1 and at intubation in Group 2& Group 3. 
Among the three groups, there is no statistical significant  difference at 
Baseline and Induction  (p >0.05).  Whereas,  there is highly significant 
difference in mean HR among the three groups at intubation, 1st 3rd and 
5th minute.  There is no significant difference between Group 2&Group 3. 
 TABLE IX            SYSTOLIC BLOOD  PRESSURE 
TIME GROUP 1 GROUP 2 GROUP 3 P 
VALUE 
BASELINE 118.5±7.9   
(102–136)  
121.95± 
5.4(106– 130) 
120.8±  6.8  
(106–130) 
>0.05 
INDUCTION 117.2± 
10.2 (100 –
136)   
119.05±6.9(100–
130) 
117.5±9.4     
(100–134)   
>0.05 
INTUBATION 135.1±8.7   
(118–160)  
123.4±4.8 (112–
132)   
126.05±7.0   
(112 –138) 
<0.05 
1 MIN 134.2±6.7   
(120–142)  
121.55±6.9(110–
138) 
123.4±6.0     
(110–130)   
<0.05 
3 MIN 130.1±5.1    
(116–136)  
118.95±7.0           
(110 – 133)  
120.1± 5.9  
(106–128)   
<0.05 
5 MIN 124.2± 7.5  
(106–138) 
116.45±6.0 
(103–128)   
117.1±4.7     
(106–122)   
<0.05 
  There is 10-35% increase in Systolic blood pressure from baseline on 
monitoring the patients  in Group-1 ,10-20%  in Group-2 and Group-3. 
The higher Systolic blood pressure  observed at intubation in Group-1 , 
Group 2 and Group 3.There is no statistical significant  difference among 
the three groups at Baseline and Induction  (p >0.05).  Whereas, there is 
highly significant difference among the three groups in mean SBP,  at 
intubation, 1st 3rd and 5th minute. .  There is no significant difference 
between  Group 2  & Group 3         
 TABLE X       DISASTOLIC  BLOOD  PRESSURE 
VARIABLE GROUP 1 GROUP 2 GROUP 3 P 
VALUE
BASELINE 75±6.1      (60–
86) 
77.4± 6.9     
(68– 90) 
74.8± 7.3   
(64 –90) 
>0.05 
INDUCTION 73.9±9.3   (58–
90) 
76.70±7.9    
(60–90) 
73.55 ±8.0 
(60–88) 
>0.05 
INTUBATION 85.45±8.9(68 –
109) 
79.05±6.5    
(70–92) 
77.9± 5.6  
(70–90) 
<0.05 
1 MIN 85.2±6.8 (70–
98) 
77.6± 5.5    
(70–90) 
76.4±5.2    
(70–90) 
<0.05 
3 MIN 83.8±6.9   (76–
98) 
76.6±6.2      
(68–90) 
74.1± 4.3   
(66–86) 
<0.05 
5 MIN 80.6±6.9  (67–
94) 
75±5.9      
(66–90) 
72.1±4.4    
(64–80) 
<0.05 
 
There is 10-25% increase in Diastolic blood pressure from baseline 
on monitoring the patients  in Group-1, much less increase in Group-2 
and Group-3. The higher Diastolic blood pressure  observed at intubation 
in Group-1 , Group 2 and Group 3.There is no statistical significant  
difference among the three groups at Baseline and Induction  (p >0.05).    
Among the three groups, there is highly significant difference in mean 
DBP at intubation, 1st ,3rd and 5th minute. There is no significant 
difference between  Group 2  & Group 3.         
 TABLE XI            MEAN ARTERIAL  PRESSURE 
VARIABLE GROUP 1 GROUP 2 GROUP 3 P 
VALUE 
BASELINE 88.15±8.2   
(67–103) 
92.3± 5.6  
(82 –101) 
90.1± 6.5(80–
103) 
>0.05 
INDUCTION 87.7 ±  9.8  
(67–104) 
90.85±6.9 
(77–102) 
88.1± 8.0(76–
102) 
>0.05 
INTUBATION 98.45±12.1 
(72–126) 
92.4±6.9   
(77–103) 
92.45±6.0(77–
103) 
>0.05 
1 MIN 99.3±9.5     
(67–111) 
92.05 
±4.9(84– 
103) 
90.55±6.8(69– 
102) 
<0.05 
3 MIN 97.25±9.7   
(62–109) 
89.55±7.8 
(66–103) 
89.25± 
4.2(79–99) 
<0.05 
5 MIN 93.85±8.48 
(69–109) 
88.9± 4.7  
(80–97) 
87.35±3.5 
(82–94) 
<0.05 
   
There is 10-25% increase in MAP from baseline on monitoring the 
patients  in Group-1, much less increase in Group-2 and Group-3. The 
higher MAP  observed at 1st minute  in Group-1 and at intubation in 
Group 2& Group 3.There is no statistical significant  difference among 
the three groups at Baseline, Induction and Intubation (p >0.05).  There is 
highly significant difference in mean MAP among the three groups, at  
1st, 3rd and 5th minute. .  There is no significant difference between  Group 
2  & Group 3.         
 Distribution of mean Heart rate response 
 
Distribution of mean SYSTOLIC BLOOD PRESSURE response 
 
 
 Distribution of mean DIASTOLIC BLOOD  PRESSURE response 
 
Distribution of MEAN ARTERIAL PRESSURE response 
 
 
 The mean onset of time and duration of action were calculated for 
all the three groups and the results were tabulated as shown in Table 
TABLE XII         Onset Time and Duration of 1st Dose 
 
Mean  
Parameter 
 
Group 1 
N=20 
Group 2 
N=20 
Group 3 
N=20 
Onset(Seconds) 102 70 61 
Duration(minutes) 25.5 39.7 57.3 
 
Mean Onset time  
 
There is significant difference among three groups on mean onset 
time (p <0.05), but there is no significant difference between the group 2 
and group 3. 
    
   Mean Duration of Blockade 
 
There is significant difference among the three groups (P <0.05) 
and also significant difference between group 2 and group 3 (p <0.05). 
 RESULTS 
 
1. Statistical analysis showed that there was significant difference 
between distribution of age and sex  among the three study groups            
(Table IV). 
2. Jaw relaxation:  On analyzing the jaw relaxation, it was 
impossible to open in one case and open with difficulty in six cases in 
Group 1. These kind of problems did not occur in Group 2 & Group 3 
(Table V). 
 Statistical analysis showed that the mean score for jaw relaxation 
was significantly higher in Group 2 & Group 3 (ie; 2.7± 0.47, 2.7 ± 0.47) 
than Group 1 (ie; 1.7± 0.73). 
3. Vocal cod position : Regarding vocal cord position ,the closed 
status (score 0) was seen in three cases in Group 1 whereas no such case 
had been encountered in Group 2 & Group 3 (Table VI). 
 Mean score for vocal cord position was significantly higher in 
Group 2 & Group 3 when compared to Group 1 (1.5 ±0.94, 2.65 ± 0.58, 
2.7 ± 0.57 in Group 1, 2 & 3 respectively) 
4.  Response to intubation : With regard to response to intubation, two 
cases had severe coughing /bucking  and seven cases  had mild coughing 
 in Group1 .These untoward events did not happen in Group 2 & Group 3 
(Table VII).  
 Mean score for response to intubation was significantly higher in 
Group 2 & Group 3 when compared to Group 1(1.55 ± 0.82, 2.75 ± 0.44, 
2.8 ± 0.41 in Group 1,2 &3 respectively) 
5. Intubation score : The analysis of intubation scores to assess 
conditions at intubation shows that higher doses result in a statistically 
significant increase in the ease of intubation. Mean total intubating score 
in Group 2 & Group3 were identical  which is significantly  higher than 
Group1 (4.75± 2.19, 8.1 ± 1.16, 8.2 ± 1.15 in Group 1,2 & 3 respectively)  
6. Acceptable intubating conditions (excellent and good scores ) were 
observed in 19 patients in Group 2 and Group 3. 4 patients had poor 
intubation score and 7 patients had fair intubation score in Group 1. No 
significant differences  in intubating conditions between rocuronium 
0.9mg/kg and 1.2mg/kg.   
7. Statistical analysis revealed that mean Heart Rate,Systolic Blood 
Pressure, Diastolic Blood Pressure ,Mean Arterial Pressure during 
intubation in Group 1 was significantly higher than in Group2 and 
Group3.(108 ± 11, 135.1 ± 8.7, 85.45 ± 8.9, 98.45 ± 12.1 in Group1, 96.4 
± 12.9 ,123.4 ± 4.8, 79.05 ± 6.5, 92.4 ± 6.9 in Group 2 & 99.15 ± 10.3, 
 126.05 ± 7, 77.9 ± 5.6, 92.45 ± 6.0 in Group 3 respectively (Tables VIII, 
IX, X, XI) 
8. Mean Heart Rate at the end of 5 minutes was higher in Group 1 
compared to Group 2 and Group 3.(99.9 ± 11.2, 86.4 ± 10.3 ,85.65 ± 6.4 
in Group, 2 and 3 respectively) 
9. The analysis showed that the onset of blockade is inversely  
proportional to the dose of rocuronium. The onset time for the intubating 
dose was significantly lower in Group 3 and between Group1 &2 ,the 
onset time was significantly lower in Group 2 (102.25 ± 29.93sec in 
Group1, 70 ± 20.13 sec in Group2 and 61.2 ± 12.95 sec in Group 3 ) 
10. The duration of neuromuscular blockade increases as the dose 
increases. Duration of action of the intubating dose was significantly 
higher in Group 3  when compared to Group 1 & 2. (25.5 ± 3.59 minutes 
in Group1, 39.75 ± 4.43 minutes in Group 2 and 57.25 ± 7.51 minutes in 
Group 3) (Table XII)  
 
 DISCUSSION 
 
           In this study, three different doses of rocuronium (0.6mg/kg, 
0.9mg/kg and 1.2mg/kg) were used for intubation and various parameters 
like onset time, duration of neuromuscular blockade, intubating 
conditions and haemodynamic changes were compared.  
 
 The onset time and duration of neuromuscular blockade were 
studied by electrical nerve stimulation The most commonly used pattern 
of electrical nerve stimulation   for evaluation of  neuromuscular function 
is the train-of-four. The study was conducted by using the peripheral 
nerve stimulator NS-100 to elicit TOF response and visual recording of 
the evoked responses were made. 
 
The time from the end of injection of the relaxant to the time when 
all four responses of TOF were abolished was taken as onset time.  
Neuromuscular function was monitored using TOF stimuli every 
5minute after giving the bolus dose of the relaxant. The  interval between 
the administration of the  bolus dose of the relaxant and the reappearance 
of the two responses to TOF was taken as the duration of action. 
 
 There was significant difference in onset time among the three 
groups. Group 3 showing fastest onset 61.2 ± 12.95 seconds  compared to 
Group 2  (70 ± 20.13 sec) and Group 1(102.25 ± 29.93 sec).  
Magonian et al. reported an onset time with succinylcholine (50.0 ± 
17.0 sec), 89.0 ± 33.0 sec. and 75.0 ± 28.0 sec after 0.6mg/kg and 
0.9mg/kg rocuronium respectively.36   
On the other hand Latorre et al reported an onset time of 48.0 ± 
16.0 sec after 1 mg/kg succinylcholine and onset time of  3.0 minutes 
after 0.6mg/kg rocuronium.37  
However Weirda et al. reported an onset time of 172.0 sec after 
rocuronium 0.6mg/kg.38 
A clinical duration of 17.4 ± 3.2 min after 0.6 mg/ kg rocuronium 
was reported by Booji et al39,while we found duration of 25.5 ± 3.59 min 
after 0.6mg/kg rocuronium.  
Mirakhur et al40 and Weirda et al. reported a clinical duration of 
30.0 min and 33.0 min respectively after 0.9mg/kg rocuronium. This 
duration is close to our observation of 39.75 ±4.43 min with 0.9 mg/ kg 
of rocuronium. 
So,eventhough the onset time is faster in group3(1.2mg/kg) there is   
prolongation of the duration of neuromuscular blockade for the first dose 
of rocuronium and this is an added disadvantage to this group.  
 Cheng CA et al
 
found that rocuronium 0.9mg/kg provides similar 
intubating conditions to suxamethonium 1.5 mg/kg using alfentanyl and 
thiopentone while rocuronium 0.6 mg/kg was inadequate.34  
Aboulish E and colleagues found that rocuronium 0.6 mg/kg with 
thiopentone 6mg/kg provides good to excellent intubating conditions at 
80 seconds and found that rocuronium is safe for mother and foetus.
35
 
Times to maximum blockade for 0.9 and 1.2 mg/kg rocuronium were the 
shortest. . 
Good to excellent tracheal intubating conditions have been reported 
within 60 seconds following rocuronium, 0.6-1.2 mg-kg-1 (2-4×ED95)  
Intubating  conditions as observed by Mirakhur et al40, Copper et al41 
Huizinga et al42 and Shukla et. al43 were good or acceptable in 95% 
patients at 60 seconds and in all patients at 90 seconds. The average 
intubating time as reported by Mirakhur et al. was 89 seconds. 
However, in our study we observed excellent to good intubating 
conditions in 45% in group 1, 100% in group 2 and in 100% in group 3. 
Our observations in rocuronium groups are very close to that observed by 
above authors. 
It is expected to have an onset time possibly as rapid as that of 
succinylcholine . But, unlike succinylcholine, rocuronium has little or no 
cardiovascular side effects31, and does not cause histamine release. Thus 
 it is ideal for rapid-sequence induction of anesthesia and may be 
preferable to succinylcholine in compromised patients in whom 
cardiovascular effects are to be avoided. Rocuronium   is currently being 
used in rapid sequence induction32,33  as an alternative to suxamethonium. 
It  has a rapid onset of action, less than 1 minute for complete 
neuromuscular block with doses of 0.9-1.2 mg/kg. 
Intubation conditions were good to excellent for rocuronium at the 
0.9 mg/kg dose(100%) and at the 1.2 mg/kg dose( 100 %), whereas 
rocuronium at the 0.6 mg/kg dose had the least number of excellent to 
good conditions (45%) and the most poor(15%) or not possible 
assessments  and few patients  could not be intubated.  
 There were  important changes or intergroup differences in mean 
arterial blood pressure and heart rate. Patients receiving  0.6mg/kg  were 
more likely to experience moderate coughing and bucking after tracheal 
tube insertion, P < 0.05, Table VII). 
Cantineau JP, et al11 (1994) studied the neuromuscular effect of 
rocuronium on the diaphragm and adductor pollicis muscles in 
anaesthetized patients and concluded that the diaphragm is more resistant 
than the adductor pollicis to rocuronium, as shown by greater ED50 and 
ED95 and faster recovery of the twitch height. The intubating dose of 
0.60 mg.kg-1 is close to the ED95 of 0.50 mg.kg-1 for the diaphragm. 
 The adductor pollicis muscle appears to be a good reflection of 
paralysis of the upper airway muscles, especially when considering 
recovery.44 
Patient ’s readiness for intubation could not be judged by the loss of 
four responses of TOF stimuli monitored at adductor pollicis.45 This may 
be because of earlier blockade of laryngeal muscles than adductor pollicis 
by rocuronium. Therefore, onset time has become overestimated as a 
predictive parameter for the rate of development of adequate intubating 
conditions. However, onset time is complementary to information 
provided by intubation score. It is very important to note that all the 
patients in  group 2 & 3 were intubated with good to excellent intubating 
conditions, when there was no diaphragmatic activity. This perhaps be 
acceptable even in emergency tracheal intubation in those patients in 
whom succinylcholine is contraindicated because of presence of other 
problems. 
Higher doses of rocuronium (0.9- 1.2mg/kg) produces ideal 
intubating conditions but the duration of acion is very much prolonged 
in 1.2mg/kg group. No further improvement in intubation conditions 
achieved by increasing the rocuronium dose from 0.9 mg/kg to 1.2 
mg/kg. 
 
  
CONCLUSION 
 
Among the three doses of rocuronium bromide used for 
endotracheal intubation in the study,  I conclude that, rocuronium 
bromide in the dose of 0.9mg/kg (Group 2) produced acceptable 
intubating conditions in 80 seconds without undue prolongation of the 
neuromuscular blockade. 
 
 
 
 
 
 
 
 
 
 
 
 
 BIBLIOGRAPHY 
 
1. G Dhonneur, K kirov, V Slavov, Ph Duvaldestin. Effects of an 
Intubating dose of Suxamethonium and Rocuronium on the larynx 
and diaphragm. Anesthesio-logy 1999 April; 90 (4): 951-55.  
2. Pery J, LeeJ, Wells G. Rocuronium versus succinylcho-line for 
rapid sequence induction. Cochrane Database Sys Rev. 2003; (1): 
CD002788  
3.  McCourt KC, Salmela L, Mirakhur RK, Carroll M, Makinen MT et 
al. Comparison of  Rocuronium and Suxamethonium for use during 
rapid sequence induc-tion of anaesthesia. Anaesthesia; 1998: 53 
(9): 867-71.  
4. Mohamed N, Cynthia AL. Pharmacology of Muscle Relaxants and 
their Antagonists in: Ronald DM, editor. Miller’s Anesthesia, 6
th 
edition. Philadelphia: Churchill Livingstone 2006; 504-05. 
5 Robert K.Stoelting, Simon C.Hiller, Pharmacology & Physiology 
in Anesthetic Practice 4th edition, chapter 8, page 238 
6. Agoston S.Onset time and evaluation of intubating conditions: 
rocuronium in perspective Eur J Anaesthesiol 1995;12(Suppl 
11):31-7 
  7. Miller DR, Wherrett C, Hull K, et al:  Cumulation characteristics 
of cisatracurium and rocuronium during continuous infusion. Can J 
Anaesth 2000; 47: 943 
8. Proost JH, Eriksson LI, Mirakhur RK, et al: Urinary, biliary and 
faecal excretion of rocuronium in humans. Br J Anaesth 2000; 85: 
717 
9. Wood SJ, Slater CR: Safety factor at the neuromuscular junction. 
Prog. Neurobiol. 2001; 64; 393 
10. Meilstelman C., Plaud B., Donati F.  A comparison of 
neuromuscular blocking effects of rocuronium bromide at the 
adductor  pollicis and laryngeal muscles.  European Journal of 
Anaesthesiology 1994: 11 (Suppl. 9) : 33-36 
11. Cantineau JP, Porte Fd’ Honneur G et al:  Neuromuscular effect of 
rocuronium on the diaphragm and adductor pollicis muscles in 
anaesthetized patients. Anaesthesiology, 1994; 81:585-590. 
12. Donati F: Neuromuscular blocking drugs for the new millennium: 
current practice, future trends – comparative pharmacology of 
neuromuscular blocking drugs. Anesth Anag 2000; 90: S2 
13. Lav Min Jc, Bekavec I, Glavnovic MI, Donati F, Bevan 
DR.Ionophoretic study of speed of action of various muscle 
relaxants , Aneathesiology 1992; 77:351-6 
 14. Kopman AF,Klewicka MM, Kopman DJ,et al: Molar potency is 
predictive of the speed of onset of neuromuscular block for agents 
of intermediate,short, and ultrashort duration. Anaesthesiology 
1999; 90: 425 
15. Wright P.M.C; James E. Cardwel, Ronald D. miller  Onset and 
duration of rocuronium and sucinylcholine at the adductor pollicis 
and laryngeal adductor muscles in anaesthetized humans. 
Anaesthesiology 1994:81:1110-1115 
16. Plaud B, Proost JH, Wierda JM, et al: Pharmacokinetics and 
pharmacodynamics of rocuronium at the vocalcords and the 
adductor pollicis in humans. Clin pharmacol Ther 1995;58; 185 
17.  Heir Tom, James Caldwell. Rapid tracheal intubation with large 
dose rocuronium. Anaesth. Analg. 2000; 90: 175-179 
18. Gupta K, Vohra V, Sood J: The role of magnesium as an adjuvant 
during general anaesthesia. Anaesthesia 2006; 61: 1058 
19.  Nitschman P, Oberkogler W, Hertsig M, Schwarz S. Comparison 
of hemodynamic effects of rocuronium bromide with those of 
vecuronium bromide in patients undergoing CABG surgery. Eur. J. 
Anaesth. 1994, 11: 113-15 (s) 
20.  Robertson EN, Hull JM, Verbeek AM, Booij LHDJ. A comparison 
of rocuronium and vecuronium: the pharmacodynamic, 
cardiovascular and intraocular effects. J Anaesth. 1994; 11 (9): 
116-21. (s) 
 21. Jerrold H, Davis G, Duggan J, Szlam F. Determination of 
hemodynamic & histamine role of rocuronium (ORG 9426) when 
administered in increased doses under N2O / O2, sufentanyl 
anesthesia. Anesth Anal 1994, 70: 318 -21.  
22. Rapp HJ, Altenmmueller CA, Waschke C: Neuromuscular 
recovery following rocuronium bromide single dose in infants. 
Paediatr Anaesth 2004; 14: 329 
23. Dr.Madhavi Barve,Dr.Roopa Sharma, Comparison of intubating 
conditions and time course action of rocuronium bromide and 
succinyl choline in paediatric patients .Indian Journal of 
Anaesthesia,December 2002: 468  
24. Scheiber G., Ribeiro P.C., Marichal A., et al. Intubating conditions 
and onset of action after rocuronium, vecuronium and atracurium 
in children.  Anaesth. Analg 1996; 83: 320-324. 
25. Gronert GA: Cardiac arrest after succinyl choline: mortality greater 
with rhabdomyolysis than receptor upregulation. Anesthesiology 
2001; 94: 523. 
26. Beven DR, Fiset P, Balendran P, et al: Pharmacodynamic 
behaviour of rocuronium in the elderly. Can J Anaesth 1993; 40: 
127 
 27. Khalil M, D’ Honneur G, Duvaldestin P. et al:  Pharmacokinetics 
and  Pharmacodynamics of rocuronium in patients with cirrhosis. 
Anesthesiology 1994; 80: 1241 
28. Paul G.Barash, Bruce F.Cullen, Robert K.Stoelting, Clinical 
Anesthesia, 6th  edition ,chapter 20, page 513 
29.  Ronald D.Miller, Miller’s Anesthesia, 6th edition, chapter 39, 
Neuromuscular Monitoring,page 1557 
30.  Cooper R, Mirakhur RK, Clerk RSJ, Boules Z. Compa-rison of 
Intubating conditions after administration of org 9426 Rocuronium. 
BJA 1992; 69: 269-273.  
31.  McCoy EP, Maddineni VR, Elliot P, Mirakhur RK, Carson IW, 
Cooper RA. Haemodynaemic effects of rocuronium during 
fentanyl anaesthesia: comparison with vecuronium. Can J Anaesth 
1993; 40 (8): 703-08. (s) 
32. Andrews JI, Kumar N, Van den Brom RH, Oikkola KT, Roest GJ 
Wright PM A large simple randomize trial of rocuronium versus 
succinylcholine in rapid sequence induction of anaesthesia along 
with propofol.  Acta Anaesthesiol Scand.  1999 Jan: 43 (1) :1-8 
33.  Laurin EG, Sakles JC, Planacek EA, Ranatapaa AA, Red JA. 
Comparison of Suxamethonium and Rocuro-nium for rapid 
 sequence intubation of emergency depa-rtment patients. Acad 
emerg Med 2000 dec; 7 (12): 1362-29.  
34.  Cheng CA, Aun CS, Gin T. Comparison of Rocuro-nium and 
Suxamethonium for rapid tracheal intubation in children. Paediatric 
Anaesth. 2002 Feb; 12 (2): 140-5.  
35.  Aboulish E, T Abbord, T Lechevalier, J ZHU, A Cha-lian and K 
Alford. Rocuronium (org 9426) for cesarean section. BJA 1994; 
73: 336-41.  
36.  Magonian T, Flannery KB, Miller RD. Comparison of rocuronium 
succinyl choline and vecuronium for rapid sequence induction of 
anaesthesia in adult patients. Anaesthesiology 1993; 79 : 913-18 (s) 
37.  Latorre F, Stanek A, Gervais HW, Kleemann PP. Intubation 
requirements after rocuronium and succinylcholine. Anästhesiol 
Intensivmed Notfallmed Schmerzther 1996; 31 (8): 470-73. (s) 
38. Wierda J.M.K.H., De Wit A.P.M. Kuizenga K, Agoston S.Clinical 
observations on the neuromuscular blocking action of org 9426, a 
new steroidal non–depolarizing agent.  British Journal of 
Anaesthesia 1990; 64:521-523. 
39.  Booji LHDJ. A dose finding study with rocuronium bromide. Eur J 
Anaesthesiol 1994;11 (Suppl 9):16-9 (s) 
 40. Mirakhur R.K. Cooper A.R. and Clarke R.S.J.  Onset and 
intubating conditons of rocuronium bromide compared to those of 
suxamethonium. European Journal of Anaesthesiology 1994; 
(Suppl.19) : 41-43 
41. Cooper R. Marikhur R.K. Maddineni V.R  Neuromuscular effects 
of rocuronium bromide during fentanyl and halothane anaesthesia. 
Anaesthesia 1993: 48: 103-105  
42.  Huizinga ACT, Vandenbrom RHG, Weirda JMKH, Hommes 
FDM, Hennis PJ. Intubating conditions and onset of neuromuscular 
block of rocuronium (Org 9426); a comparison with 
suxamethonium. Acta     Anaesthesiol Scand 1992; 36: 463-68. (s) 
43. Shukla A, Dubey KP; Sharma MSN: Comparative Evaluation of 
Hemodynamic effects & intubating conditions after administration 
of ORG 9426 and Succinylcholine. Indian J Anaesth: 2004: 476 - 
79 (s) 
44. Wylie and Churchill- Davidson’ s A Practice Of Anesthesia -7th 
edition,monitoring  neuromuscular block,chapter 15,page 283  
45.  Lam AM, Pavlin EG, Visco E, Taraday J. Rocuronium versus 
succinylcholine-atracurium for tracheal intuba-tion and 
maintenance relaxation during propofol anes-thesia. J Clin Anesth; 
2000: 12 (6): 449-53. 
 46.Ronald D.Miller, Anesthesia for Trauma, Anesthetics for induction of 
anesthesia, Miller’s Anesthesia, Sixth edition, chapter 63, 2457-2458 
47.Ronald D.Miller, Anesthesia for Eye, Ear, Nose and Throat Surgery,  
Miller’s Anesthesia, Sixth edition, chapter 65, 2532- 2533 
48.David H. Chestnut, Anesthesia for Cesarean Section, Obstetric 
Anesthesia –Principles and Practice, Third edition, chapter 25, page 436 
49.Wylie and Churchill- Davidson’s A Practice of Anesthesia, seventh 
edition, Neuromuscular blocking agents and their antagonists, chapter 
36,page 590.  
 
            
  
Name                                                 Age/Sex                          IP NO:                            Wt : 
 
DIAGNOSIS:                                                                  Surgery : 
 
 
Preop Assesment  : 
 
Investigations :                                                             O/E : 
 
 
Premedication:                                                 
Shifting to O.T. 
I.V. line Securing 
Preoxygenation :           
Induction :                                          
Muscle relaxant used 
           Group I       : Inj. Rocuronium  0.6mg/ kg 
          Group II       : Inj. Rocuronium  0.9mg/ kg 
         Group III       : Inj. Rocuronium  1.2mg/ kg                              
Maintenance : 
Onset  Time of neuromuscular blockade : 
Intubation at 80 sec. 
 
PROFORMA 
 
 
 
 
 
 
Haemoglobin %  Urine-  Albumin and sugar, Packed cell volume   
Blood- urea, sugar, creatinine, Liver Function Tests, E.C.G.  X-Ray Chest 
 
 
 Intubation Score:   Cooper Scoring  System 
Score Jaw relaxation Vocal Cords Response to intubation 
0 Poor (impossible) Closed Severe coughing or bucking 
1 Minimal(difficult) Closing Mild coughing 
2 Moderate (fair) Moving Slight diaphragmatic movement 
3 Good  (easy) Open None 
Total Score  : Excellent (8-9)/  Good (6-7)/   Fair (3-5) /  Poor(0-2) 
Haemodynamic Response to Intubation : 
No Name Age Sex 
Baseline Induction Intubation 1 min 3 min 5 min 
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Duration of action of  Intubating dose : 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Masterchart
 GROUP 1 
S.NO  SURGERY 
ONSET 
TIME (sec) 
DURATION 
OF 
BLOCKADE 
(min) 
INTUBATING CONDITIONS AT 80 SEC 
JAW 
RELAXATI0N 
VOCAL 
CORDS 
RESPONSE 
TO 
INTUBATION
INTUBATION 
SCORE 
INTUBATION 
GRADE 
1  Post auricular flap   90  25  2  2  2  6  Good 
2  Inguinal herniorraphy  100 20 1 0  1 2 Poor
3  Fibroadenoma excision  80  20  2  1  1  4  Fair 
4  Fibroadenoma excision  55  25  3  3  2  8  Excellent 
5  Lap sterilization‐ TAT  60  25  3  3  2  8  Excellent 
6  MTP & LAP TAT  100 30 2 2  3 7 Good
7  Hemithyroidectomy  90  25  2  2  2  6  Good 
8  Open&internal fixation ‐ elbow   110  25  0  1  1  2  Poor 
9  Lumpectomy breast  80 30 2 3  2 7 Good
10  Implant removal radius  120  25  1  0  0  1  Poor 
11  Fibroadenoma excision  130  25  1  1  2  4  Fair 
12  Tonsillectomy  120  25  1  2  1  4  Fair 
13  Fibroadenoma excision  90  30  2  2  3  7  Good 
14  Adeno Tonsillectomy  60  20  2  2  2  6  Good 
15  Fibroadenoma excision  100  30  2  2  2  6  Good 
16  Fibroadenoma excision  110  30  2  1  2  5  Fair 
17  Fibroadenoma excision  180  20  1  0  0  1  Poor 
18  Interval appendiceetomy  130  25  2  1  1  4  Fair 
19  Tonsillectomy  100  25  2  1  1  4  Fair 
20  Fibroadenoma excision  140 30 1 1  1 3 Fair
 GROUP 1 
 
NAME  IPNO  WEIGHT(kg) SEX AGE(years) BASELINE  INDUCTION  INTUBATION 
S.NO    HR  SBP DBP MAP  HR  SBP DBP MAP  HR  SBP DBP MAP
1  Elavarasi  34196  45  F  20  86  110 76  88  88  108  80  89  96  120  88  99 
2  Prabu  4160  48  M  23  88  126 80  95  96  124  84  97  120 140  98  112 
3  Chitra  10809  40  F  25  84  120 80  93  82  120  82  95  90  128  88  101 
4  Priya  13023  50  F  20  106 120 80  93  100 116  78  91  101 118  80  93 
5  Prema  3376  60  F  32  79  109 77  87  86  110  80  90  100 160  109  126 
6  Dhanaselan  13397  55  F  30  106 124 78  93  112 128  74  92  120 138  68  91 
7  Venda  13711  80  F  35  90  136 86  103  94  136  88  104  110 140  90  107 
8  Murugan  13419  75  M  35  85  126 86  99  90  128  90  103  106 138  96  111 
9  Suganthi  14377  45  F  20  86  124 76  92  88  126  80  95  96  136  84  101 
10  Manikandan  15073  57  M  21  104 111 71  85  102 110  70  84  116 130  84  100 
11  Jayanthi  19433  43  F  26  70  120 70  87  76  110  60  87  97  140  90  106 
12  Sheela  16489  46  F  21  82  120 76  91  88  128  78  95  100 132  86  91 
13  Pushpalatha  16954  45  F  22  78  116 74  88  86  110  70  83  96  138  90  106 
14  Barathi  88496  40  M  20  90  102 60  72  96  100  58  72  110 130  78  92 
15  Parimala  18760  45  F  36  84  120 68  82  90  110  60  76  100 140  78  98 
16  Prema  20857  54  F  18  98  110 76  87  106 100  70  80  120 136  80  74 
17  Sathiya  20390  45  F  23  92  120 70  67  94  122  72  67  126 138  76  96 
18  Kumaresan  20810  48  M  20  108 126 76  92  110 130  74  92  120 140  86  72 
19  Sasikala  20683  60  F  23  98  110 70  83  100 112  60  77  120 130  80  96 
20  Soundari  19971  43  F  40  92  120 70  86  96  116  70  85  116 130  80  97 
 
 
 GROUP 1 
 
IPNO 
1MIN  3 MIN  5 MIN 
S.NO  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP 
1  34196  94  120  84  96  90  126  86  99  88  118  84  95 
2  4160  120  138  98  111  126  136  96  109  108  130  90  103 
3  10809  96  128  90  102  108  136  94  108  94  138  94  109 
4  13023  96  120  70  87  97  116  98  91  95  110  80  90 
5  3376  98  140  86  104  136  136  80  99  126  126  78  94 
6  13397  130  140  86  104  128  130  84  99  120  128  80  96 
7  13711  118  140  92  108  110  136  90  105  100  130  88  102 
8  13419  104  130  94  106  100  128  92  104  92  128  90  103 
9  14377  96  130  84  100  92  132  86  102  90  130  88  102 
10  15073  118  130  84  100  110  122  82  95  102  116  85  94 
11  19433  100  138  88  104  98  130  80  104  90  126  76  92 
12  16489  106  136  90  105  102  130  80  97  90  120  76  91 
13  16954  110  140  92  108  100  130  86  101  86  126  78  94 
14  88496  108  130  76  91  106  128  76  93  99  106  67  81 
15  18760  105  142  80  100  96  136  76  96  90  130  70  90 
16  20857  126  130  78  95  116  126  76  62  106  120  80  93 
17  20390  120  140  90  67  110  130  78  95  100  128  76  69 
18  20810  126  142  82  102  120  134  80  98  117  126  78  94 
19  20683  124  134  82  99  120  130  80  97  108  120  76  91 
20  19971  106  136  78  97  100  130  76  91  98  128  78  94 
 
 
 GROUP 2 
S.
N
O 
SURGERY 
ONSET 
TIME 
(Sec) 
DURATION 
OF 
BLOCKADE 
(min) 
INTUBATING CONDITIONS AT 80 SEC 
JAW 
RELAXATI0N 
VOCAL 
CORDS 
RESPONSE TO 
INTUBATION 
INTUBATION 
SCORE 
INTUBATION 
GRADE 
 
1  Open reduction &internal fixation 
80  50  3  3  3  9 
Excellent 
2  Inguinal herniorraphy  65 40 2 3  3 8 Excellent
3  Inguinal herniorraphy  70  35  3  3  3  9  Excellent 
4  Bilateral Inguinal hernia ‐Mesh repair  120  40  3  3  3  9  Excellent 
5  Ureterorenoscopy  75  30  2  3  3  8  Excellent 
6  Fibroadenoma excision  45  40  3  3  2  8  Excellent 
7  MTP & LAP Sterilisation  45  40  3  3  3  9  Excellent 
8  K‐Wire fixation‐ Ankle #  80  40  3  3  3  9  Excellent 
9  Tonsillectomy  100  40  3  2  3  8  Excellent 
10   Excision‐ Fibroadenoma  100  45  3  3  3  9  Excellent 
11  Sebaceous cyst  face‐excision  70  35  2  3  2  7  Good 
12  Cross Finger Flap –Index finger  70  45  2  2  2  6  Good 
13  Superficial parotidectomy  60  40  3  3  3  9  Excellent 
14  Endoscopic sinus surgery  80  40  2  2  2  6  Good 
15  Open reduction&internal fixation‐Patella 
fracture 
65  40  3  3  3  9 
Excellent 
16  Pilonidal sinus –Excision  60  35  2  3  3  8  Excellent 
17  Inguinal herniorraphy  65  40  3  2  2  7  Good 
18  L4‐L5 Discectomy  60  45  3  3  3  9  Excellent 
 
19 
Acetabular fracture‐ Open  
reduction&internal fixation 
35  35  3  3  3  9 
Excellent 
20  Endoscopic sinus surgery  55 40 3 2  3 8 Excellent 
 
 GROUP2 
  NAME  IPNO  WEIGHT SEX AGE  BASELINE  INDUCTION  INTUBATION 
S.NO  kg  years HR  SBP DBP  MAP HR  SBP DBP MAP HR  SBP DBP MAP
1  Immanuvel  14039 70 M  34 78 122 72  89 86 115 86 96 90 120 80 93
2  Anandhan  5163 60 M  32 88 120 80  93 82 122 82 95 82 122 82 95
3  Chandran  5676 48 M  29 90 130 86  101 92 130 88 102 88 128 86 100
4  Ravi  10933 60 M  30 80 126 86  99 80 126 84 98 82 128 86 100
5  Kannan  12462 65 M  40 88 128 78  95 90 130 80 97 90 122 82 98
6  Kamatchi  77208 45 F  20 86 124 80  95 90 120 76 91 92 112 78 78
7  Jagavalli  13374 55 F  25 88 122 82  95 90 118 80 93 94 124 78 89
8  Thiagu  10322 53 M  35 8 120 82  95 84 122 86 98 86 124 88 100
9  Valli  14622 45 F  20 89 127 72  91 90 126 74 92 92 132 79 93
10  Govindammal  14902 50 F  40 96 120 90  100 98 120 90 100 115 126 92 103
11  Antony  19503 85 M  39 90 126 80  95 96 120 70 86 100 130 76 94
12  Kumar  15545 55 M  35 78 122 78  93 80 120 76 91 84 124 80 95
13  Murugan  17739 70 M  39 120 130 86  100 126 120 80 93 128 124 86 98
14  Manjula  88686 40 F  35 84 120 80  93 90 110 60 77 100 120 70 77
15  Suresh  20035 20 M  20 108 106 70  82 112 100 70 80 116 116 74 88
16  Nathiya  20393 60 F  20 97 116 70  85 100 110 68 82 106 124 80 95
17  Prabaharan  21721 75 M  38 90 120 70  88 92 120 76 91 92 128 70 89
18  Murali  20868 55 M  34 110 120 68  85 112 116 70 85 114 118 74 88
19  Loganathan  21207 60 M  35 76 118 68  85 80 116 70 85 84 120 70 86
20  Uma  24251 45 F  37 86 122 70  87 90 120 68 85 94 126 70 89
 
 
 GROUP 2 
 
IPNO 
1MIN  3 MIN  5 MIN 
S.NO  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP 
1  14039  86  118  76 90 82 120 70  86 78 122 74 90
2  5163  80  120  80 93 78 120 78  92 82 122 82 95
3  5676  84  120  80 93 84 122 82  95 82 118 80 93
4  10933  80  124  84 97 80 120 82  95 78 120 78 92
5  12462  86  126  80 95 85 128 78  95 85 128 80 96
6  77208  88  110  78 89 84 110 80  90 84 103 68 82
7  13374  83  112  76 88 82 110 80  90 83 112 82 92
8  10322  84  120  80 93 86 124 82  96 84 120 78 92
9  14622  104  133  90 103 119 133 90  103 122 120 70 88
10  14902  104  120  88 99 102 122 88  100 102 110 90 97
11  19503  100  130  76 94 92 120 76  90 86 122 74 90
12  15545  84  124  80 95 80 120 70  87 82 120 70 87
13  17739  106  120  70 86 100 110 72  85 80 112 70 84
14  88686  100  138  80 99 98 130 78  95 90 120 76 91
15  20035  114  120  72 88 110 110 70  83 90 106 68 80
16  20393  106  120  76 91 100 110 70  83 92 112 74 86
17  21721  90  120  72 88 86 122 74  90 84 116 76 89
18  20868  102  110  72 84 96 110 74  86 90 112 72 85
19  21207  86  120  70 86 80 118 68  84 74 116 66 82
20  24251  94  126  72 90 86 120 70  66 80 118 72 87
 
 
 GROUP 3 
  SURGERY  ONSET TIME
DURATION 
OF 
BLOCKADE 
INTUBATING CONDITIONS AT 80 SEC 
S.
N
O 
 
(Sec)  (min) 
JAW 
RELAXATI0N 
VOCAL 
CORDS 
RESPONSE 
TO 
INTUBATION 
INTUBATION 
SCORE 
INTUBATION 
GRADE 
1  Appendicectomy  45 45 3 3 3 9 Excellent
2  Intramedullary nailing  64  50  3  3  3  9  Excellent 
3  Open reduction‐Internal fixation‐ Radius  50  55  2  3  3  8  Excellent 
4  Open reduction ‐DCS‐Femur fracture  65  60  3  3  3  9  Excellent 
5  Olecranon facture‐ Tension‐Band wiring 45 50 3 2 3 8 Excellent
6  Hand injury –Exploration  60  65  3  3  3  9  Excellent 
 
7 
Foot metatarsal fracture –K Wire 
fixation 
90  60  3  3  3  9 
Excellent 
8  Hemithyroidectomy  65  55  3  3  2  8  Excellent 
9  Cholecystectomy  55  70  3  3  3  9  Excellent 
10  L5‐S1 Microdissectomy  50 55 2 2 3 7 Good
11  Superficial Parotidectomy  50  50  3  3  3  9  Excellent 
12  Complete Thyroidectomy  80  70  3  3  3  9  Excellent 
13  Appendicectomy  85 55 3 3 3 9 Excellent
14  Appendicectomy  70  50  3  2  3  8  Excellent 
15  Superficial Parotidectomy  55  55  3  3  3  9  Excellent 
16  Fracture Humerus‐ External fixation  60  55  2  3  3  8  Excellent 
17  Superficial Parotidectomy  50 70 3 3 3 9 Excellent
18  Ulna & Radius fracture‐ Internal fixation  50  50  2  2  2  6  Good 
19  Vascular malformation‐Excision  65  60  2  2  2  6  Good 
20  Post.cruciate ligament‐ Screw fixation  70  65  2  3  3  8  Excellent 
 
 GROUP 3 
  NAME  IPNO  WEIGHT  SEX  AGE  BASELINE  INDUCTION  INTUBATION 
S.NO  kg  years HR  SBP  DBP  MAP  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP 
1  Sekar  6388  55  M  38  86  120  84  96  88  122  86  98  84  120  80  93 
2  Thiyagu  10332  50  M  28  88  120  74  93  90  120  76  91  96  122  78  93 
3  Karthikeyan  11209  4  M  21  86  122  76  91  90  128  74  91  94  130  78  95 
4  Muthukrishnan  11305  50  M  35  90  130  80  97  92  134  84  101  92  134  86  102 
5  Panchatcharam  13267  47  M  30  92  122  80  94  90  120  82  97  100  124  80  95 
6  Raj  13408  47  M  26  90  126  86  99  94  130  88  102  98  130  90  103 
7  Murugan  16777  50  M  20  90  106  68  80  96  100  66  77  100  112  70  84 
8  Jeyanthi  16493  65  F  30  80  126  66  86  88  116  70  85  90  130  76  94 
9  Lily  16136  55  F  40  78  110  76  87  82  100  70  80  86  116  80  92 
10  Kumar  18168  60  M  33  78  120  66  84  88  110  60  76  90  128  70  89 
11  Usha  19195  40  F  25  88  120  68  85  92  116  70  85  98  122  76  91 
12  Maheswari  19476  45  F  22  96  116  70  85  100  110  65  80  15  125  70  88 
13  Srinivasan  20070  55  M  35  110  130  90  103  112  122  86  98  120  134  88  103 
14  Lakshmi  12824  50  F  32  106  120  70  86  110  126  72  90  114  130  76  94 
15  Sakthivel  20723  70  M  39  102  110  70  83  106  106  68  80  110  116  78  90 
16  Venkatesan  18032  60  M  26  101  130  80  97  108  126  70  88  116  132  74  93 
17  Perumal  95518  50  M  30  76  122  70  87  80  120  68  85  90  134  78  92 
18  Purushothaman  22882  45  M  22  90  116  64  81  94  114  64  80  100  124  70  88 
19  Ongaran  23636  40  M  17  100  120  78  92  106  110  76  87  110  120  80  93 
20  Loganathan  21207  60  M  35  76  130  80  96  80  120  76  91  90  138  80  77 
 
 GROUP 3 
 
IPNO 
1MIN  3 MIN  5 MIN 
S.NO  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP  HR  SBP  DBP  MAP 
1  6388  84  120  78  92  82  118  78  91  82  118  76  91 
2  10332  95  120  78  92  86  120  76  91  84  116  76  89 
3  11209  94  130  76  94  90  128  74  92  88  120  70  87 
4  11305  88  126  78  94  84  120  76  91  85  122  78  93 
5  13267  9  120  78  92  90  122  78  93  84  122  80  94 
6  13408  93  130  90  102  90  126  86  99  88  120  80  93 
7  16777  96  110  70  83  86  106  66  79  84  108  70  83 
8  16493  88  124  70  88  80  120  68  85  78  120  70  87 
9  16136  85  120  78  92  84  120  76  91  80  116  78  90 
10  18168  92  130  74  93  86  126  72  90  80  120  64  91 
11  19195  90  120  70  86  86  118  74  89  80  110  68  82 
12  19476  100  118  72  87  96  116  72  86  90  110  70  83 
13  20070  116  130  86  101  110  126  76  92  90  120  70  86 
14  12824  106  126  80  95  104  120  76  90  96  116  72  86 
15  20723  108  114  76  88  104  110  76  87  98  106  74  84 
16  18032  110  130  76  94  92  126  72  90  88  120  70  86 
17  95518  80  130  70  90  80  120  70  86  74  120  68  85 
18  22882  98  122  72  88  96  124  70  88  94  120  68  85 
19  23636  106  118  78  91  100  110  70  83  92  118  70  86 
20  21207  88  130  78  69  80  126  76  92  78  120  70  86 
  
